FLT3 and acute myeloid leukemia: in a cohort of 100 samples from AML patients with intermediate-risk cytogenetics, high CDC25A mRNA levels only predicted a higher clonogenic potential in Flt3-ITD samples, and the CDC25 inhibitor IRC-083864 only had an antiproliferative effect and only induced monocytic differentiation for Flt3-ITD, but not for Flt3-wt AML cells.